For Immediate Release

Contact: Ray Russo (908) 313 -7172

Ray.Russo@vero-biotech.com

Mike Gentile

Atlanta-based biotech company expands with addition of renowned Duke University School of Medicine and Health System respiratory and critical care expert.

October 5, 2018, Atlanta, GA – Vero Biotech LLC, a biopharmaceutical company focused on the design, development and commercialization of next generation inhaled nitric oxide (NO), today announced the appointment of Michael Gentile, MBA, RRT, FAARC, FCCM, as Vice President of Medical Affairs. Mr. Gentile joins Vero Biotech from Duke University School of Medicine and Health System in Durham, NC, and brings to Vero over 30 years of clinical practice, clinical research, teaching, and leadership. He has served in key positions for societies such as AARC, SCCM, ACCP, and ACHE.

Mr. Gentile will be responsible for development of hospital education, clinical development, clinical operations, and data analysis and will contribute his expertise to solution development.

“Michael is an outstanding addition to Vero’s senior management team. He brings a wealth of practical knowledge and experience to our company. We consider Michael’s addition an endorsement of Vero’s commitment to providing valuable solutions in the highly complex acute care hospital setting,”

said Brent Furse, President and CEO at Vero Biotech. “Mike is highly respected and well recognized in the Respiratory and Critical Care communities.”

“I am excited to be part of the Vero Biotech team. My entire career has been spent seeking solutions for patients and clinicians, and I look forward to continuing those efforts with Vero,” said Mr. Gentile.

About Vero Biotech

Vero Biotech is a biopharmaceutical company focused on the design, development and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions. For more information, please visit www.vero-biotech.com.

ATLANTA —Vero Biotech has opened a new 15,585-square-foot headquarters at the Georgia Institute of Technology’s Technology Enterprise Park in Atlanta. The biopharmaceutical company, formerly known as GeNO LLC, designs, develops and commercializes products for patients with pulmonary and cardiac diseases. Vero Biotech will move its administrative, research & development and manufacturing departments from its current office in Cocoa, Fla., to the new space over the next six to 12 months. The company plans to double its operations, hiring up to 40 new employees over the next year. In addition, Vero Biotech will partner with Georgia Tech to provide hands-on experience and internship opportunities for students. Chad Koenig and Ben Jackson of Cushman & Wakefield represented Vero Biotech in the lease negotiations, and Enio Guerra and Dick Bowers of Richard Bowers & Co. represented Georgia Tech.

The biotechnology company left Florida for the Peach State, setting up shop in a 15,600-square-foot space at Georgia Tech’s Technology Enterprise Park.

Atlanta has reeled in another headquarters tenant. Vero Biotech recently wrapped up the relocation of its home base from Cocoa, Fla., to Georgia Tech’s Technology Enterprise Park (TEP) in Midtown Atlanta.

Vero Biotech has set up shop in a nearly 15,600-square-foot space at 387 Technology Circle NW. With its name on the tenant roster of the 236,700-square-foot office and lab building, the emerging biotechnology company has attained a certain instant cachet, as the 11-acre park is widely considered the premier biotech research park in the city.

The decision to move the company to Atlanta was multifaceted, but one of the main reasons was that Atlanta is a growing hub for pharmaceutical and biotech companies. The city is full of innovators such as Vero Biotech, and we wanted to work within that environment and also closely with Georgia Tech,” Namita Khanna, executive director of strategic development with Vero Biotech, told Commercial Property Executive.

Vero Biotech’s Class A accommodations at TEP include laboratories with state-of-the-art clean rooms, administrative support space and a conference facility. Cushman & Wakefield represented the tenant in the lease transaction, while Richard Bowers & Co. stood in for the landlord.

Vero Biotech officially opened its new headquarters on April 6. The company will relocate its administrative, R&D and manufacturing operations over the next six to 12 months. Vero Biotech also plans to add 40 positions to its current staff of 65 within the next year.

“Relocating to Atlanta also gave us the ability to attract top talent who were willing to move to the area based upon the demographics and all that Atlanta has to offer such as a rich history, skyrocketing rates of job growth, and desirable neighborhoods,” Khanna said. “In addition to that, Atlanta has a world class airport, top dining options, and a growing city with a reasonable cost of living.”